You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
|
|---|---|
| Published in |
BMC Pediatrics, June 2010
|
| DOI | 10.1186/1471-2431-10-38 |
| Pubmed ID | |
| Authors |
Pilar Fernández, Adrian Trenholme, Katia Abarca, M Pamela Griffin, Micki Hultquist, Brian Harris, Genevieve A Losonsky, the Motavizumab Study Group |
| Abstract |
Respiratory syncytial virus (RSV) is an important pathogen causing annual epidemics of bronchiolitis and pneumonia among infants worldwide. High-risk infants currently receive RSV prophylaxis with palivizumab, a humanized RSV monoclonal antibody (MAb). In preclinical in vitro and in vivo (cotton-rat model) studies, motavizumab, a new RSV MAb, was shown to have greater anti-RSV activity than palivizumab. Motavizumab is currently under review for licensing approval. Since both MAbs may be available concurrently, this study evaluated their safety and tolerability when administered sequentially during the same RSV season. |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Belgium | 1 | 2% |
| Unknown | 63 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 16% |
| Researcher | 10 | 16% |
| Student > Bachelor | 9 | 14% |
| Student > Master | 9 | 14% |
| Other | 4 | 6% |
| Other | 5 | 8% |
| Unknown | 17 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 39% |
| Agricultural and Biological Sciences | 8 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 18 | 28% |